PE20140872A1 - Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple - Google Patents

Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple

Info

Publication number
PE20140872A1
PE20140872A1 PE2013001357A PE2013001357A PE20140872A1 PE 20140872 A1 PE20140872 A1 PE 20140872A1 PE 2013001357 A PE2013001357 A PE 2013001357A PE 2013001357 A PE2013001357 A PE 2013001357A PE 20140872 A1 PE20140872 A1 PE 20140872A1
Authority
PE
Peru
Prior art keywords
laquinimod
improve
patients
life
multiple sclerosis
Prior art date
Application number
PE2013001357A
Other languages
English (en)
Spanish (es)
Inventor
Nora Tarcic
Dan Bar-Zohar
Dina Kofler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140872(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PE20140872A1 publication Critical patent/PE20140872A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2013001357A 2010-12-07 2011-12-06 Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple PE20140872A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42074210P 2010-12-07 2010-12-07
US201161542996P 2011-10-04 2011-10-04

Publications (1)

Publication Number Publication Date
PE20140872A1 true PE20140872A1 (es) 2014-08-09

Family

ID=46162796

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001357A PE20140872A1 (es) 2010-12-07 2011-12-06 Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple

Country Status (19)

Country Link
US (1) US20120142730A1 (enExample)
EP (1) EP2648732A4 (enExample)
JP (2) JP2013544887A (enExample)
KR (1) KR20130124518A (enExample)
CN (1) CN103260624B (enExample)
AU (2) AU2011338647A1 (enExample)
BR (1) BR112013014061A2 (enExample)
CA (1) CA2820586A1 (enExample)
CL (1) CL2013001602A1 (enExample)
EA (1) EA201390827A1 (enExample)
IL (1) IL250726A0 (enExample)
MX (1) MX2013006464A (enExample)
NZ (1) NZ611628A (enExample)
PE (1) PE20140872A1 (enExample)
PH (1) PH12013501193A1 (enExample)
SG (2) SG190449A1 (enExample)
UA (1) UA111959C2 (enExample)
WO (1) WO2012078591A1 (enExample)
ZA (1) ZA201304237B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937642B1 (en) * 2005-10-19 2014-09-10 Teva Pharmaceutical Industries Ltd Crystals of laquinimod sodium, and process for the manufacture thereof
EP2977049A1 (en) 2007-12-20 2016-01-27 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
RS54707B1 (sr) * 2009-07-30 2016-08-31 Teva Pharmaceutical Industries Ltd. Tretman kronove bolesti lakvinimodom
PL3064206T3 (pl) 2009-08-10 2020-02-28 Active Biotech Ab Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
NZ602510A (en) * 2010-03-03 2014-11-28 Teva Pharma Treatment of lupus nephritis using laquinimod
SG183513A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
KR20140138725A (ko) 2012-02-16 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
IN2015DN03219A (enExample) * 2012-09-27 2015-10-02 Teva Pharma
EA201590726A1 (ru) * 2012-10-12 2015-10-30 Тева Фармасьютикал Индастриз Лтд. Лахинимод для уменьшения таламического поражения при рассеянном склерозе
HK1212936A1 (zh) 2012-11-07 2016-06-24 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
SG11201505818WA (en) * 2013-02-15 2015-08-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
HK1220125A1 (zh) 2013-03-14 2017-04-28 Teva Pharmaceutical Industries Ltd. 拉喹莫德的透皮配方
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2014364447A1 (en) * 2013-12-20 2016-08-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod to delay Huntington's disease progression
US20160331742A1 (en) * 2014-01-17 2016-11-17 Teva Pharmaceutical Industries, Ltd. Treatment of crohn's disease using low doses of laquinimod
UY36099A (es) 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
US10537566B2 (en) 2014-10-16 2020-01-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
CN112770748A (zh) * 2018-10-09 2021-05-07 美迪诺亚公司 异丁司特和干扰素-β的组合及其使用方法
CA3145269A1 (en) * 2019-07-22 2021-01-28 Michel BURCKLEN Use of ponesimod for the treatment of multiple sclerosis
CN110688373A (zh) * 2019-09-17 2020-01-14 杭州绿度信息技术有限公司 一种基于逻辑回归的offset方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560100B2 (en) * 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
BRPI0713694A2 (pt) * 2006-06-12 2012-10-30 Teva Pharma composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica
PT2653873T (pt) * 2007-02-08 2022-07-26 Biogen Ma Inc Composições e utilizações para o tratamento de esclerose múltipla
CN107308162A (zh) * 2009-06-19 2017-11-03 泰华制药工业有限公司 利用拉喹莫德治疗多发性硬化

Also Published As

Publication number Publication date
UA111959C2 (uk) 2016-07-11
CN103260624B (zh) 2015-06-03
WO2012078591A8 (en) 2012-08-02
CN103260624A (zh) 2013-08-21
CA2820586A1 (en) 2012-06-14
PH12013501193A1 (en) 2013-07-15
JP2013544887A (ja) 2013-12-19
US20120142730A1 (en) 2012-06-07
EP2648732A1 (en) 2013-10-16
CL2013001602A1 (es) 2013-10-25
NZ611628A (en) 2015-06-26
AU2011338647A8 (en) 2013-09-05
AU2017202055A1 (en) 2017-04-20
AU2011338647A1 (en) 2013-07-04
EA201390827A1 (ru) 2013-12-30
SG190449A1 (en) 2013-07-31
SG10201509831XA (en) 2015-12-30
BR112013014061A2 (pt) 2016-09-13
ZA201304237B (en) 2014-08-27
JP2017095476A (ja) 2017-06-01
KR20130124518A (ko) 2013-11-14
WO2012078591A1 (en) 2012-06-14
EP2648732A4 (en) 2014-04-30
MX2013006464A (es) 2013-07-29
IL250726A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
PE20140872A1 (es) Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
RU2014109074A (ru) ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
NZ589445A (en) Rasagiline for parkinson's disease modification
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
PH12014500386A1 (en) Combination treatment for hepatitis c
MX2014013039A (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
FI3439660T3 (fi) Pimobendaanin käyttö sydämen koon pienentämiseen ja kliinisten oireiden alkamisen hidastamiseen potilaissa, joilla on hiippaläppäsairaudesta johtuva oireeton sydämen vajaatoiminta
MX344303B (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
MX2015014939A (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
NZ597675A (en) Medicament for the long term nsaid use
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
AR080380A1 (es) Tratamiento de la demencia tipo alzheimer con masitinib
NZ599227A (en) Therapeutic agent for chronic pain
NZ726034A (en) Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine

Legal Events

Date Code Title Description
FC Refusal